Correlation Between Santen Pharmaceutical and Mega Uranium

Can any of the company-specific risk be diversified away by investing in both Santen Pharmaceutical and Mega Uranium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Santen Pharmaceutical and Mega Uranium into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Santen Pharmaceutical Co and Mega Uranium, you can compare the effects of market volatilities on Santen Pharmaceutical and Mega Uranium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Santen Pharmaceutical with a short position of Mega Uranium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Santen Pharmaceutical and Mega Uranium.

Diversification Opportunities for Santen Pharmaceutical and Mega Uranium

-0.45

Correlation Coefficient

Santen Pharmaceutical  Mega Uranium

Very good diversification

The 3 months correlation between Santen and Mega is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Santen Pharmaceutical Co and Mega Uranium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mega Uranium and Santen Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Santen Pharmaceutical Co are associated (or correlated) with Mega Uranium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mega Uranium has no effect on the direction of Santen Pharmaceutical i.e., Santen Pharmaceutical and Mega Uranium go up and down completely randomly.

Pair Corralation between Santen Pharmaceutical and Mega Uranium

Assuming the 90 days horizon Santen Pharmaceutical Co is expected to under-perform the Mega Uranium. But the pink sheet apears to be less risky and, when comparing its historical volatility, Santen Pharmaceutical Co is 1.05 times less risky than Mega Uranium. The pink sheet trades about -0.15 of its potential returns per unit of risk. The Mega Uranium is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  23.00  in Mega Uranium on September 15, 2024 and sell it today you would earn a total of  1.00  from holding Mega Uranium or generate 4.35% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Santen Pharmaceutical Co  vs.  Mega Uranium

Santen Pharmaceutical

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Santen Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, Santen Pharmaceutical is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Mega Uranium

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Mega Uranium are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Mega Uranium reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Santen Pharmaceutical and Mega Uranium

The main advantage of trading using opposite Santen Pharmaceutical and Mega Uranium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Santen Pharmaceutical position performs unexpectedly, Mega Uranium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mega Uranium will offset losses from the drop in Mega Uranium's long position.

The idea behind Santen Pharmaceutical Co and Mega Uranium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.